Channing Global Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
Channing Global Advisors's NVO Position: Q3 2026 in Review
Channing Global Advisors reduced its Novo Nordisk (NVO) stake by 35% in Q3 2026, selling an estimated $696K and leaving 27,792 shares worth $1.05M. The position accounts for 0.55% of the portfolio, ranked #29.
Channing Global Advisors first reported a position in NVO in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.06M in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Channing Global Advisors held 27,792 shares of Novo Nordisk worth $1.05M as of Q3 2026.
- Channing Global Advisors sold 15,091 Novo Nordisk shares in Q3 2026, an estimated $696K.
- Novo Nordisk made up 0.55% of Channing Global Advisors's portfolio in Q3 2026, its #29 holding.
- Channing Global Advisors first reported a position in Novo Nordisk in Q4 2021 and has held it in 15 quarters since.
- Channing Global Advisors's Novo Nordisk position peaked at $2.06M in Q2 2026.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Channing Global Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.